CVS Health (CVS) Reaches Proposed FTC Settlement on Insulin Pricing

CVS Health Corporation (NYSE:CVS) is one of the 10 High PE Stocks Insiders Are Buying.

On March 24, 2026, CVS Health Corporation (NYSE:CVS) reached a proposed settlement with the Federal Trade Commission related to insulin pricing, according to a Reuters report. The company said the process is expected to conclude in the coming weeks, though final terms remain pending, while regulators have raised concerns that the pricing model may encourage higher list prices and steer patients toward more expensive drugs.

On March 12, 2026, Bernstein analyst Lance Wilkes upgraded CVS Health Corporation (NYSE:CVS) to Outperform from Market Perform with a price target of $94 from $91, citing “attractive exposure” to a Medicare Advantage turnaround and potential for more stable pharmacy earnings following reform impacts. Lance Wilkes also described recent regulatory developments as a “clearing event.”

CVS Health (CVS) Reaches Proposed FTC Settlement on Insulin Pricing

Pixabay/Public Domain

On March 11, 2026, CVS Health’s Aetna agreed to pay $117.7M to resolve allegations it violated the False Claims Act by submitting inaccurate diagnosis data tied to Medicare Advantage payments.

CVS Health Corporation (NYSE:CVS) provides healthcare services across insurance, pharmacy, and health solutions segments in the United States.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.